(NASDAQ: CNTB) Connect Biopharma Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Connect Biopharma Holdings's revenue in 2025 is N/A.On average, 1 Wall Street analysts forecast CNTB's revenue for 2025 to be $2,194,661,712, with the lowest CNTB revenue forecast at $2,194,661,712, and the highest CNTB revenue forecast at $2,194,661,712. On average, 1 Wall Street analysts forecast CNTB's revenue for 2026 to be $1,111,221,120, with the lowest CNTB revenue forecast at $1,111,221,120, and the highest CNTB revenue forecast at $1,111,221,120.
In 2027, CNTB is forecast to generate $1,916,856,432 in revenue, with the lowest revenue forecast at $1,916,856,432 and the highest revenue forecast at $1,916,856,432.